Samsung Bioepis and Teva have expanded their existing strategic partnership to develop and commercialize biosimilar candidates, specifically targeting up to six different products. Among these are SB41, which is aimed at being a biosimilar for Fasenra® (benralizumab), and SB44, intended as a biosimilar for Ilaris® (canakinumab). The companies have outlined plans for collaboration across multiple markets, including the United States, Europe, and Canada, with an option to expand the partnership to additional territories as needed.
Biosimilars are biologic medical products highly similar to already approved reference products, considered an important aspect of improving patient access to medications and managing healthcare costs. This partnership combines the innovative capabilities of Samsung Bioepis, known for its expertise in developing biosimilars, with Teva’s established market presence. As leaders in the pharmaceutical industry, both companies are focusing on leveraging their strengths to address the growing demand for biosimilars in various health markets.
The move comes at a time when the biosimilar market is evolving rapidly due to increasing pressures on healthcare systems and the need for cost-effective treatment options. With this partnership, both companies aim to contribute to the broader healthcare landscape, providing patients and providers with alternative therapies that can offer similar efficacy to existing products at potentially lower costs. The collaboration marks a significant step in both companies’ strategies to enhance their biosimilar portfolios and improve accessibility to critical medications globally.
Analyzed Canadian Outlets (1)
1 headline